ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/29/2026

1. LFTO
2. QNT
3. VRDN
4. CMCSA
5. NVDA
6. INIO
7. IRDM
8. HONA
9. HON
10. SPY

Go back to ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

Acelyrin Inc (SLRN) PT Lowered to $6 at Citi

August 14, 2024 9:25 AM EDT

Citi analyst Samantha Semenkow lowered the price target on Acelyrin Inc (NASDAQ: SLRN) to $6.00 (from $8.00) while maintaining a Neutral rating.

The analyst comments "Acelyrin announced a strategic reprioritization to focus resources on development of lonigutamab (anti-IGFR1) in thyroid eye disease. The company will... More